Study guide
10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy
WHNP-BC Women's Health Nurse Practitioner Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: About the WHNP-BC Exam
WHNP-BC Exam Facts, Blueprint & Study Plan
2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening
1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening
3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention
2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites
4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers
3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers
5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility
4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies
6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy
5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion
7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health
6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis
8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care
7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction
9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care
8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy
10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth
9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency
11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions
10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn
12 Chapter 11: Intrapartum Principles & Fetal Surveillance
11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies
13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications
12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs
14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions
13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold
15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders
14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders
16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health
15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis
17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care
16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care
18 Chapter 17: Assessment, Diagnostic Testing & Interpretation
17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities
19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing
18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation
20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities
19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care
10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy
Key Takeaways Explain This Topic AI
Monochorionic twins need ultrasound every 2 weeks from 16 weeks to detect twin-twin transfusion syndrome; ACOG delivery timing is 38 0/7–38 6/7 weeks for dichorionic and 34 0/7–37 6/7 weeks for monochorionic-diamniotic twins.
SMFM defines fetal growth restriction as an estimated fetal weight or abdominal circumference below the 10th percentile; umbilical artery Doppler findings guide surveillance and delivery timing.
ACOG suggests offering cesarean birth for suspected macrosomia when the estimated fetal weight is at least 5,000 g without diabetes or at least 4,500 g with diabetes.
External cephalic version is offered at 37 0/7 weeks or later for breech presentation when there are no contraindications, and Rh(D)-negative patients receive anti-D immune globulin.
Late-term pregnancy begins at 41 0/7 weeks and postterm at 42 0/7 weeks; antenatal testing starts at 41 weeks, induction can be considered from 41 0/7 weeks, and ACOG recommends induction after 42 0/7 and by 42 6/7 weeks.
Last updated: October 2026
Multiple Gestation
Twins occur in about 3% of U.S. births, more often with assisted reproduction and older maternal age.
Maternal risks: Preeclampsia (aspirin is indicated), gestational diabetes, anemia, hyperemesis, preterm birth (about 60% of twins deliver before 37 weeks), and postpartum hemorrhage.
Fetal risks: Preterm birth, growth restriction, growth discordance (20% or more), anomalies, and stillbirth; monochorionic twins add twin-twin transfusion syndrome (TTTS) , which occurs in about 10%–15% of monochorionic-diamniotic pairs, and monoamniotic twins add cord entanglement.
Care: Determine chorionicity in the first trimester. Ultrasound every 4 weeks or so for dichorionic twins; every 2 weeks from 16 weeks for monochorionic twins to watch for TTTS (polyhydramnios in the recipient and oligohydramnios in the donor). Weight gain goal for a normal-BMI twin pregnancy is about 37–54 lb.
- Twin Type ACOG Delivery Timing (uncomplicated)
- Dichorionic-diamniotic 38 0/7–38 6/7 weeks
- Monochorionic-diamniotic 34 0/7–37 6/7 weeks
- Monochorionic-monoamniotic 32 0/7–34 0/7 weeks (usually by cesarean)
Vaginal birth is reasonable when the first twin is cephalic; cesarean is usual when the first twin is not cephalic.
Fetal Growth Restriction (FGR)
Definition (SMFM 2020): Estimated fetal weight (EFW) or abdominal circumference below the 10th percentile ; severe FGR is below the 3rd percentile. Small for gestational age (SGA) describes a newborn whose birth weight is below the 10th percentile.
Causes: Maternal (hypertension, preeclampsia, diabetes with vascular disease, smoking, substance use, malnutrition, autoimmune disease), placental (abnormal spiral artery remodeling, abruption, cord abnormalities), and fetal (aneuploidy, structural anomalies, infection such as CMV).
Evaluation: Detailed anatomy survey; genetic counseling and diagnostic testing for early-onset FGR (before 32 weeks) or FGR with anomalies or polyhydramnios; CMV testing.
Surveillance: Umbilical artery Doppler is the key test; add amniotic fluid assessment and NST or biophysical profile.
- Doppler Finding Typical Delivery Timing (SMFM)
- EFW 3rd–10th percentile, normal Doppler 38 0/7–39 0/7 weeks
- EFW below the 3rd percentile or decreased diastolic flow 37 0/7 weeks
- Absent end-diastolic velocity 33 0/7–34 0/7 weeks
- Reversed end-diastolic velocity 30 0/7–32 0/7 weeks
Give antenatal corticosteroids when delivery before 34 weeks is likely, and magnesium for neuroprotection before 32 weeks.
Macrosomia and Large for Gestational Age
Definitions: Birth weight of 4,000 g or 4,500 g or more (macrosomia); large for gestational age is above the 90th percentile.
Risk factors: Diabetes (pregestational or gestational), obesity, excessive weight gain, prior macrosomic infant, and postterm pregnancy.
Limitations: Ultrasound and clinical estimates of fetal weight are imprecise.
ACOG Practice Bulletin 216: Suspected macrosomia alone is not an indication for induction before 39 weeks. Offer scheduled cesarean when EFW is at least 5,000 g without diabetes or at least 4,500 g with diabetes to reduce shoulder dystocia and brachial plexus injury.
Amniotic Fluid Abnormalities
Finding Definition Common Causes Management
Oligohydramnios Deepest vertical pocket <2 cm (preferred) or AFI ≤5 cm PPROM, placental insufficiency (FGR), renal agenesis or obstruction, postterm pregnancy, NSAIDs or ACE inhibitors Rule out rupture of membranes and FGR; hydrate; increased surveillance; isolated oligohydramnios at term is delivered at 36 0/7–37 6/7 weeks
Polyhydramnios Deepest vertical pocket ≥8 cm or AFI ≥24 cm Maternal diabetes, fetal swallowing defects (esophageal or duodenal atresia, neuromuscular disorders), fetal anemia or hydrops, twins with TTTS, idiopathic Diabetes screening, detailed anatomy scan, antibody screen, infection testing; risks include preterm labor, malpresentation, cord prolapse at rupture, and postpartum hemorrhage
Malpresentation
Breech presentation affects about 3%–4% of term pregnancies (frank, complete, or footling).
External cephalic version (ECV): Offer at 37 0/7 weeks or later (when spontaneous version is unlikely but an emergency term delivery is acceptable). Success is about 50%–60%, higher in multiparous patients. Contraindications include placenta previa, a nonreassuring fetal tracing, and any contraindication to vaginal birth. Use fetal monitoring before and after, consider tocolysis with terbutaline, and give anti-D immune globulin to Rh(D)-negative patients .
Delivery: Planned cesarean is common for persistent breech; planned vaginal breech birth is reasonable in selected cases under hospital protocols with experienced clinicians (ACOG Committee Opinion 745).
Transverse lie at term needs ECV or cesarean, and rupture of membranes with a transverse lie raises the risk of cord prolapse. Face, brow, and compound presentations are identified in labor; a mentum posterior face presentation cannot deliver vaginally.
Late-Term and Postterm Pregnancy
Definitions: Late term is 41 0/7–41 6/7 weeks ; postterm is 42 0/7 weeks or later . Accurate first-trimester dating sharply reduces false postterm diagnoses.
Risks: Stillbirth, macrosomia and shoulder dystocia, oligohydramnios, meconium aspiration, and placental insufficiency (postmaturity syndrome).
Management (ACOG Practice Bulletin 146): Begin antenatal surveillance (for example, NST plus amniotic fluid assessment) at 41 0/7 weeks . Induction can be considered from 41 0/7 to 42 0/7 weeks and is recommended after 42 0/7 and by 42 6/7 weeks. Trials such as SWEPIS and INDEX found better perinatal outcomes with induction at 41 weeks, so many clinicians now induce at 41 weeks. Elective induction at 39 weeks in low-risk nulliparous patients is a reasonable option: the ARRIVE trial found it did not increase, and modestly lowered, cesarean rates.